


- INSTITUTE OF RESEARCH AND EDUCATION OF RESPIRATORY DISEASES
- MEDITERRANEAN ASSOCIATION FOR THE STUDY OF INFLAMMATORY DISORDERS

1st
EDUCATIONAL SEMINAR
OF THE HELLENIC SOCIETY
FOR THE STUDY
OF FIBROSIS

Fibrosis across Organ Systems

January
27
2024

The seminar is granted with 8 credits of continuing medical education (CME-CPD)



.....
.....

FOR YOUR
REGISTRATION

[CLICK HERE](#)

National
Hellenic
Research
Foundation,
Athens

SCIENTIFIC PROGRAM

ΠΡΟΣΩΠΟ ΜΕ ΠΡΟΣΩΠΟ ΜΕ ΤΗΝ ΗΩΣΙΝΟΦΙΛΙΚΗ ΦΛΕΓΜΟΝΗ



Αποδεδειγμένη
αποτελεσματικότητα
σε 4 σοβαρές
πρωσινοφιλικές παθήσεις¹



Επιβεβαιωμένο στην
πραγματική ζωή σε ασθενείς
με σοβαρό πρωσινοφιλικό άσθμα²

Το **Nucala** (μεπολιζουμάμπη) ενδείκνυται ως επιπρόσθετη θεραπεία για σοβαρό ανθεκτικό πρωσινοφιλικό άσθμα (SEA) σε ενήλικες, εφήβους και παιδιά ηλικίας 6 ετών και άνω. Το **Nucala** ενδείκνυται επίσης για χρόνια ρινοκολπίτιδα με ρινικούς πολύποδες (CRSwNP), πρωσινοφιλική κοκκιωμάτωση με πολυαγγειίτιδα (EGPA) και του υπερπρωσινοφιλικού συνδρόμου (HES)¹. Εκτός εάν σημειώνεται διαφορετικά, οι εικόνες και τα προφίλ ασθενών προορίζονται μόνο για επεξηγηματικούς σκοπούς.

Για την Περίληψη των Χαρακτηριστικών του Προϊόντος σκανάρετε το QR code. Σε έντυπη μορφή είναι διαθέσιμη κατόπιν αιτήσεως στην εταιρεία.



Σύνοψη Προφίλ ασφαλείας¹:

Σοβαρό πρωσινοφιλικό άσθμα: Σε μελέτες ελεγχόμενες με εικονικό φάρμακο σε ενήλικες και εφήβους ασθενείς με σοβαρό ανθεκτικό πρωσινοφιλικό άσθμα, οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες κατά τη διάρκεια της θεραπείας ήταν κεφαλαλγία (20%), αντιδράσεις στη θέση ένεσης (8%) και σοφραλγία (6%).

CRSwNP: Σε μία ελεγχόμενη με εικονικό φάρμακο μελέτη σε ασθενείς με CRSwNP, οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες κατά τη διάρκεια της θεραπείας ήταν κεφαλαλγία (18%) και σοφραλγία (7%).

EGPA: Σε μία ελεγχόμενη με εικονικό φάρμακο μελέτη σε ασθενείς με EGPA, οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες κατά τη διάρκεια της θεραπείας ήταν κεφαλαλγία (32%), αντιδράσεις της θέσης ένεσης (15%) και σοφραλγία (13%). Συστηματικές αλλεργικές αντιδράσεις/αντιδράσεις υπερευαίσθησης αναφέρθηκαν από το 4% των ασθενών με EGPA.

HES: Σε μία ελεγχόμενη με εικονικό φάρμακο μελέτη σε ασθενείς με HES, οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες κατά τη διάρκεια της θεραπείας ήταν κεφαλαλγία (13%), ουρολιμωξη (9%), αντιδράσεις της θέσης ένεσης και πυρεξία (7% η κάθε μία).

Βιβλιογραφία:

1. Περίληψη Χαρακτηριστικών Προϊόντος Nucala, Οκτώβριος 2022 2. Kallieri et al, Allergy 2022, RELight: A two-year REal-Life study of mepolizumab in patients with Severe Eosinophilic Asthma in Greece: evaluating the multiple components of response.

Φαρμακευτικό προϊόν για το οποίο απαιτείται περιορισμένη ιατρική συνταγή. Η εικόνα και το προφίλ ασθενούς χρησιμοποιείται μόνο για επεξηγηματικούς σκοπούς. Το Nucala θα πρέπει να χορηγείται από ιατρούς με εμπειρία στη διάγνωση και την αντιμετώπιση του σοβαρού ανθεκτικού πρωσινοφιλικού άσθματος, της GRSwNP, της EGPA ή και του HES.

Η Περίληψη των Χαρακτηριστικών του Προϊόντος σε έντυπη μορφή είναι διαθέσιμη κατόπιν αιτήσεως στην εταιρεία.

Λ.Τ.*: NUCALA INJ SOL 100MG 1 προγεμισμένη σύριγγα: 1.033,95€ NUCALA INJ SOL 100MG 1 προγεμισμένη συσκευή τύπου πένας: 1.033,95€ % επιχορήγησης από τους οργανισμούς κοινωνικών ασφαλίσεων: 100%. Τα ανωτέρω ισχύουν κατά την ημερομηνία σύνταξης του υλικού.

Παρακαλούμε επικοινωνήστε με την εταιρεία για επιβεβαίωση πλήρους ημερησίως δεδομένων, για οποιαδήποτε πληροφορία ή/και αναφορά Ανεπιθύμητων Ενέργειών στο τηλέφωνο 210 6882100.


*αφορά μόνο σε πωλήσεις ιδιωτικού φαρμακείου.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Τα εμπορικά σήματα ανήκουν ή έχουν παραχωρηθεί στον Όμιλο εταιρειών GSK.
©2023 Όμιλος εταιρειών GSK ή δικαιούχου του Όμιλου GSK.

GlaxoSmithKline ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.Β.Ε.
Λ. Κηφισίας 266, 15232 Αθήνα, Τηλ. 210 6882100

www.gsk.com



1st
EDUCATIONAL SEMINAR OF THE
HELLENIC SOCIETY FOR THE STUDY OF FIBROSIS

Fibrosis across Organ Systems

WELCOME LETTER

Dear colleagues,

During the last years the concept of fibrotic remodeling across organ systems has been highlighted as the major pathogenic event leading to organ failure and increased patients' mortality. It is now well established that 45% of deaths in the developed countries can be attributed to mechanisms related to fibroproliferative disorders. Unfortunately, available treatments only halt disease progression, thus leaving patients with major disability and impaired quality of life. The interaction between different specialties has, so far, led to important therapeutic achievements through drug repurposing such as the INBUILD and SENCIS randomized controlled trials where FDA-approved anti-fibrotic compounds for the treatment of IPF have been successfully applied to patients with different types of lung fibrosis including connective-tissue and granulomatous-related. In line with this concept, we have recently created an association for the study of fibrotic diseases across organ systems to expedite scientific interactions and fuel research studies that could lead to similar. To further expand this concept, we are organizing the first scientific seminar in Greece called "**FIBROSIS ACROSS ORGAN SYSTEMS**". The seminar aims to unite different medical specialties and scientific communities with a modern holistic approach to patients with different types of fibroproliferative disorders, in order to achieve their treatment optimization. It includes rich topics that not only respond to key clinical issues but also extend to the area of translational and basic research highlighting the importance of mechanistic thinking in the diagnosis and treatment of the complex fibrotic disease.

We will be looking forward to your fruitful participation in the inspiring venue of The National Hellenic Research Foundation, in Athens on the **27th of January 2024**.

Argyrios Tzouvelekis
*Associate Professor of
Respiratory Medicine,
University of Patras, Greece
Associate Professor Adjunct,
Yale School of Medicine, USA*

Petros Sfikakis
*Professor of Internal Medicine
and Rheumatology
University of Athens, Greece
EULAR Centre of Excellence
in Rheumatology 2021-2026*



1st

EDUCATIONAL SEMINAR OF THE
HELLENIC SOCIETY FOR THE STUDY OF FIBROSIS

■ National Hellenic Research Foundation
Athens

SCIENTIFIC PROGRAM / January 27, 2024

09.45-10:00 **Welcome address – Why this Seminar?**
Petros Sfikakis, Argyrios Tzouvelekis

10.00-13.00 **Molecular mechanisms of fibrotic diseases –
Differences and similarities across organ systems**
Chairing persons: Evangelos Chologkitas, Sophie Mavrogeni,
Argyrios Tzouvelekis, Charalampos Vlachopoulos

- Pulmonary fibrosis, **Theodoros Karampitsakos**
 - Liver fibrosis, **Antonios Chatzigeorgiou**
 - Scleroderma, **Nikos Vlachogiannis**
 - Intestinal fibrosis, **Georgios Bamias**
 - In vitro models of fibrosis using subepithelial myofibroblasts,
Eirini Filidou
 - Cardiac fibrosis, **Georgios Markousis-Mavrogenis**
 - Renal fibrosis, **Aglaia Chalkia**
-

13:00-13:30 COFFEE BREAK

13.30-16.00 **Diagnostic and prognostic dilemmas in the management
of fibrotic interstitial lung diseases**
Chairing persons: Athena Gogali, Dimitrios Karokis,
Petros Sfikakis, Vassillis Tzilas

- IPF, **Maria Molina Molina**
- Granulomatous Diseases (Sarcoidosis, HP), **Paolo Spagnolo**
- PH-ILD, **Iraklis Tsagkaris**
- RA-ILD, **Georgios Fragkoulis**
- SCL-ILD, **Marco Matucci-Cerinic**

Fibrosis

across Organ Systems

..... / January 27, 2024

SCIENTIFIC PROGRAM /

16:00-17:00 LUNCH BREAK

17.00-19.00 **The role of anti-fibrotic compounds in the management of fibrosis**

Chairing persons: Aikaterini Antoniou, Demosthenes Bouros,
Theodoros Dimitroulas, Julien Guiot

- The role of pirfenidone, **Eirini Vasarmidi**

- The role of nintedanib, **Anna-Maria Hoffmann**

- The role of tocilizumab, **Stylianos Panopoulos**

- The role of rituximab, **Dimitrios Daousis**

- Novel antifibrotic compounds, **Jose Herazo Maya**

19.00-19.30 **State of the art: management of airways remodeling and fibrosis**

Chairing persons: **Georgios Hillas, Stylianos Loukides,**
Andriana Papaioannou

Speaker: **Konstantinos Kostikas**

Highlights and Concluding remarks

Petros Sfikakis, Argyrios Tzouvelekis



1st

EDUCATIONAL SEMINAR OF THE
HELLENIC SOCIETY FOR THE STUDY OF FIBROSIS

■ National Hellenic Research Foundation
Athens

FACULTY /

A

Antoniou Aikaterini

Professor of Respiratory Medicine, Head of ERS Assembly 12 Interstitial Lung Diseases, Head of Molecular & Cellular Pneumology Lab, Department of Respiratory Medicine, School of Medicine, University of Crete, Greece

B

Bamias Georgios

MD, PhD, Professor of Gastroenterology, GI Unit, 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens, "Sotiria" Chest Diseases Hospital, Athens, Greece

Bouros Demosthenes

Emeritus Professor, MD, PhD, FERS, FAPSR, FCCP, Athens Medical School, National and Kapodistrian University of Athens, Athens Medical Center, Greece

C

Chalkia Aglaia

Nephrologist, Research Fellow in Vasculitis and Lupus Research Group, Department of Medicine, University of Cambridge, UK supported by HSS-Stavros Niarchos Foundation through Hellenic Society of Nephrology and European Renal Association, Consultant in Nephrology Department, "Hippokratation" General Hospital of Athens, Greece

Chatzigeorgiou Antonios

MD, PhD, Associate Professor of Experimental and Clinical Physiology, National and Kapodistrian University of Athens, Greece

Cholongitas Evangelos

MD, PhD, Professor in Medicine-Hepatology, 1st Department of Internal Medicine, Athens Medical School, National and Kapodistrian University of Athens, Greece

D

Daousis Dimitrios

Associate Professor of Internal Medicine - Rheumatology, Department of Rheumatology, University of Patras Medical School, Greece

Dimitroulas Theodoros

Associate Professor of Rheumatology, School of Medicine, Aristotle University of Thessaloniki, Greece

F

Filidou Eirini

Molecular Biologist, MSc, PhD
Post-Doctoral Researcher at Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, Greece

Fragkoulis Georgios

Assistant Professor of Internal Medicine - Rheumatology, National and Kapodistrian University of Athens, Athens General Hospital "Laiko", Greece

G

Gogali Athena

Consultant in Respiratory Medicine, Respiratory Medicine Department, University Hospital of Ioannina, Greece

Guiot Julien

Pulmonologist, Associate Professor, University Hospital of Liège, University of Liège, Belgium

Fibrosis across Organ Systems

..... / January 27, 2024

FACULTY

H

Herazo-Maya D. Jose

MD, Ubben Endowed Chair and Associate Professor of Medicine, Chief of Pulmonary, Critical Care and Sleep Medicine, Director, Ubben Center for Pulmonary Fibrosis Research, University of South Florida, Morsani College of Medicine, Associate Director, Critical Care Medicine, Tampa General Hospital, Interim co-director, Center for Advanced Lung Disease, Tampa General Hospital

Hillas Georgios

MD, PhD, Consultant in Respiratory Medicine, 5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece, Coordinator - COPD Working Group, HTS

Hoffmann Anna-Maria

Head of the Strategic Area of Inflammatory and Fibrotic Diseases, Department of Rheumatology, Oslo University Hospital

K

Karampitsakos Theodoros

MD, MSc, PhD, Postdoctoral Scholar, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Ubben Center for Pulmonary Fibrosis Research, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

Karakis Dimitrios

Rheumatologist, Patras, President, Greek Society for Rheumatology, Greece

Kostikas Konstantinos

MD, PhD, FCCP, FERS, Professor of Respiratory Medicine, University of Ioannina, Head Respiratory Medicine Department, University Hospital of Ioannina, Greece

L

Loukides Stylianos

President of Hellenic Thoracic Society, Professor of Pulmonology, National and Kapodistrian University of Athens, Greece

M

Markousis-Mavrogenis Georgios

MD, Cardiology Resident, University Hospital Heidelberg, Heidelberg, Germany
Research Assistant, National and Kapodistrian University of Athens, Athens, Greece

Matucci-Cerinic Marco

Professor of Rheumatology, Vita-Salute University San Raffaele & UNIRAR, Ospedale San Raffaele, Milano, Italy

Mavrogeni Sophie

MD, PhD, Vice Director of Cardiac Clinic, Onassis Cardiac Center, Visiting Professor of Cardiovascular Magnetic Resonance, National and Kapodistrian University of Athens, Greece and University of Padova, Italy

Molina Molina Maria

Professor, Chief of ILD Unit and Research Group, Respiratory Department, University Hospital of Bellvitge, Scientific Director of National Research network in Respiratory Diseases (CIBERES), Spain

P

Panopoulos Stylianos

Rheumatologist, Academic Fellow, 1st Propaedeutic and Internal Medicine Department, Athens General Hospital "Laiko", Greece



1st

EDUCATIONAL SEMINAR OF THE
HELLENIC SOCIETY FOR THE STUDY OF FIBROSIS

■ National Hellenic Research Foundation
Athens

FACULTY

Papaioannou Andriana

Assistant Professor of Respiratory Medicine,
Athens Medical School, National and
Kapodistrian University of Athens,
1st Respiratory Medicine Department
“Sotiria” Chest Diseases Hospital,
Athens, Greece

S

Sfikakis Petros

Professor of Internal Medicine and
Rheumatology, Head, 1st Propaedeutic and
Internal Medicine Department,
Athens Medical School, National and
Kapodistrian University of Athens,
Athens General Hospital “Laiko”, Greece

Spagnolo Paolo

Professor, Respiratory Disease Unit,
Department of Cardiac, Thoracic,
Vascular Science and Public Health,
University of Padova, Padova, Italy

T

Tsakaris Iraklis

Professor of Pulmonary and Critical Care
Medicine, National and Kapodistrian
University of Athens, Director of 2nd Critical
Care Department, Attikon University Hospital,
Head of Multidisciplinary Pulmonary
Hypertension Clinic, Attikon University Hospital

Tzilas Vassilis

MD, PhD, Respiratory Consultant,
5th Respiratory Department, “Sotiria” Chest
Diseases Hospital, Athens, Greece

Tzouvelekis Argyrios

MD, PhD, MSc, Associate Professor of
Internal and Respiratory Medicine,
Head, Department of Respiratory Medicine,
University of Patras, Greece,
Associate Professor Adjunct,
Yale School of Medicine, USA

V

Vasarmidi Eirini

MD, MSc, PhD, Pulmonologist, Assistant
Consultant, Early Career Members
Representative (Hellenic Thoracic Society),
Department of Respiratory Medicine and
Laboratory of Molecular and Cellular
Pneumology, School of Medicine,
University of Crete, Heraklion, Crete, Greece

Vlachogiannis Nikos

MD, PhD, Postdoctoral Researcher,
1st Department of Propaedeutic Internal
Medicine and Department of Physiology,
Athens Medical School, National and
Kapodistrian University of Athens, Greece

Vlachopoulos Charalampos

Professor of Cardiology, Athens Medical School,
National and Kapodistrian University of Athens,
1st Department of Cardiology, “Hippokraton”
General Hospital of Athens, Greece

Fibrosis across Organ Systems

..... / January 27, 2024

GENERAL INFORMATION

This **Hybrid Seminar** will be held on **Saturday January 27th, 2024**, with physical presence and online participation.

LOCATION

The National Hellenic Research Foundation (N.H.R.F)

Address: 48 Vassileos Constantinou Avenue, 11635, Athens

Tel: +30 210.72.73.516

REGISTRATION

Registration for the Seminar is mandatory in order for someone to receive the respective Certificate of Attendance. Registration may take place through the online platform, by completing the registration form on the following link:

REGISTER

or on-site at the secretariat during the Seminar.

By filling out the form in the above link, you will receive a digital confirmation (electronic badge) at the email you registered with.

You may save the proof of registration e-mail, on your mobile phone (as a pdf file or in the Apple wallet / Android application) or print it to present and scan it in the event's premises for entering the venue.

CREDITS FOR CONTINUING MEDICAL EDUCATION (CME)

The Seminar is granted with 8 credits (CME-CPD) by the Panhellenic Medical Association.

Certificates of attendance will be sent electronically to participants after the end of the Seminar. In order for participants to be entitled for a Certificate of Attendance, they should have attended a minimum of 60% of the total hours of the Scientific Program. Also, according to the instructions of the P.M.A. (Panhellenic Medical Association) the above attendance time is a pre-requisite for obtaining the CME-CPD credits.



1st

EDUCATIONAL SEMINAR OF THE
HELLENIC SOCIETY FOR THE STUDY OF FIBROSIS

■ National Hellenic Research Foundation
Athens

GENERAL INFORMATION

TECHNICAL SECRETARIAT

During the Seminar there will be a technical secretariat to receive the presentations and address any technical issues. Speakers are kindly requested to deliver their presentations to the technical secretariat, at least one hour prior to their scheduled participation.

SAFETY MEASURES

People with respiratory symptoms and/or fever, are not allowed to enter the Conference area. During your stay in the Conference area, it is recommended to respect social distancing. Masks and gloves will be available for any delegate who wishes to use them.

Hand sanitizing devices will be placed in various spots of the Conference venue. There will be frequent natural ventilation of the space and regular checks will be carried out by the security staff and the Conference Secretariat.

ORGANIZATION

- INSTITUTE OF RESEARCH AND EDUCATION OF RESPIRATORY DISEASES
- MEDITERRANEAN ASSOCIATION FOR THE STUDY OF INFLAMMATORY DISORDERS
- HELLENIC SOCIETY FOR THE STUDY OF FIBROSIS

CONFERENCE SECRETARIAT



E: info@eventure.gr

T: +30 2160702929 / +30 6945454165



Fibrosis across Organ Systems

..... / January 27, 2024

SPONSORS /

On behalf of the organizing committee,
we would like to extend our deepest gratitude
to the below sponsors for their contribution.



ΣΤΗΝ ΙΔΙΟΠΑΘΗ ΠΝΕΥΜΟΝΙΚΗ ΙΝΩΣΗ¹

**Pirfenidone
axunio**
πιρφενιδόνη

PIR/PEN/UA010_2023/03

axunio



Κάτοχος Άδειας Κυκλοφορίας
axunio Pharma GmbH
Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany,
Tel: +494038023214, medinfo@axunio.eu

Αντιπρόσωπος Κατόχου Άδειας Κυκλοφορίας
ELPEN A.E. - Φαρμακευτική Βιομηχανία
Λεωφ. Μεταβόλων 95, Πικερμιά Αττικής 190 09,
Τηλ.: 2111865000, www.elpen.gr

1. Περίληψη Χαρακτηριστικών Προϊόντος

Χρησιμοποιείται με περιορισμένη ιατρική συνταγή από ειδικό
ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

Αναφέρετε κάθε εικαζόμενη/πιθανολογούμενη
ανεπιθύμητη ενέργεια απευθείας στον ΕΟΦ,
σύμφωνα με το εθνικό σύστημα αναφοράς
ανεπιθύμητων ενεργειών

Περιγραφή	Λιστική τιμή
PIRFENIDONE AXUNIO F.C.TAB 267MG/TAB 252 ΔΙΣΚΙΑ ΣΕ BLISTERS	1.386,95 €
PIRFENIDONE AXUNIO F.C.TAB 267MG/TAB 63 ΔΙΣΚΙΑ ΣΕ BLISTERS	366,39 €
PIRFENIDONE AXUNIO F.C.TAB 801MG/TAB 84 ΔΙΣΚΙΑ ΣΕ BLISTERS	1.386,95 €

Για την ΠΧΠ
σαρώστε εδώ

